Systemic adjuvant treatment for premenopausal node-negative breast cancer

By Castiglione-Gertsch M.   Gelber R.D.   O'Neill A.   Coates A.S.   Goldhirsch A.  

European Journal of Cancer, Vol. 36, Iss. 4, 2000-03 ,pp. : 549-550

Elsevier

Access to resources Recommend Favorite

Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

By degeorges A.  

Breast Cancer Research and Treatment, Vol. 47, Iss. 1, 1998-01 ,pp. : 47-55

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients - effect of adjuvant chemotherapy

By Poikonen P.   Saarto T.   Elomaa I.   Joensuu H.   Blomqvist C.  

European Journal of Cancer, Vol. 36, Iss. 1, 2000-01 ,pp. : 43-48

Elsevier

Access to resources Recommend Favorite

Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23

By Land Stephanie   Kopec Jacek   Yothers Greg   Anderson Stewart   Day Richard   Tang Gong   Ganz Patricia   Fisher Bernard   Wolmark Norman  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 153-164

Springer Publishing Company

Access to resources Recommend Favorite

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite